CD52 and multiple sclerosis: Cases of neurological autoimmunity including antibody-associated encephalitis has been reported in multiple sclerosis patients treated with the CD52 (e.g., alemtuzumab) or CD25 (e.g., daclizumab) protein inhibitors (127–129).